Abraham Shaked, President of the American Society of Transplant Surgeons, Appointed to Tissera's Scientific Advisory Board.

Business Editors/Health/Medical Writers

TEL AVIV, Israel--(BUSINESS WIRE)--April 13, 2004

Tissera, Inc. (OTCBB:TSSR), a biotechnology company dedicated to the development and commercialization of tissue transplantation therapies utilizing novel tissue precursor regeneration technologies for the treatment of disease and organ transplantation, today announced the appointment of renowned Professor and Surgeon, Abraham Shaked, M.D., Ph.D., to the company's Scientific Advisory Board.

Dr. Shaked currently holds the position of Professor of Surgery at the Hospital of the University of Pennsylvania as well as serving as the Director of the PENN Transplant Center and Chief of the Division of Transplantation Surgery. Dr. Shaked is currently President of the American Society of Transplant Surgeons. Dr. Shaked is an internationally known leader in the field of transplantation. For many years, his practice has focused on the surgical treatment of liver and liver related diseases. He is one of the most experienced surgeons in the U.S. in adult and pediatric liver transplantation, and has a special interest in hepatobiliary malignancy, as well as biliary reconstruction.

According to Dr. Vicki Rabenou, CEO of Tissera, "Dr. Shaked is an invaluable asset to our Scientific Advisory Board. He brings over a decade of experience in Liver medical research and transplantation expertise that will provide our scientists with unprecedented insight and advice from a true pioneer in the industry. We are enthralled to have him join our Board."

Dr. Shaked's academic record is reflected by his achievements in basic laboratory research and support for clinical science investigation. His laboratory efforts focus on the application of gene transfer technology in the transplant setting. He has published over 150 manuscripts and is a member of the editorial boards of Transplantation, Graft and Liver Transplantation. In addition, Dr. Shaked has been the recipient of numerous awards for his outstanding work in the transplantation field including the American Liver Foundation Physician of the Year Award, the American Society of Transplant Surgeons Faculty Career Development Award and the Arthur A. Afuses Award for Outstanding Chief Resident at Mount Sinai Medical Center, New York.

"Tissera's work in organogenesis has the potential to radically change the transplantation practice," said Dr. Shaked. "I was honored to be asked to join Tissera's Scientific Advisory Board. This is an incredible group of scientists on the cusp of medical breakthroughs that could potentially solve the ever alarming quandry of organ shortages."

Tissera is advancing the field of transplantation and tissue regeneration technologies. The growth and development of human organ precursors in Tissera's research facilities are expected to improve and lengthen the lives of tens of thousands of people in need of donor tissue and organs to treat a broad spectrum of fatal illnesses in the near future.

About Tissera

Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera licensed the worldwide exclusive rights to the technology developed at the renowned Weizmann Institute of Science in Israel led by Professor Yair Reisner, who currently serves as the Chief of Tissera's Scientific Advisory Board. In this research, scientists successfully implanted embryonic human and porcine kidney precursor tissues in mice, which grew into functional kidneys. This research was published in Nature Medicine and attracted worldwide scientific and media attention. For more information, please visit: www.tissera.com.

Safe Harbor Statement

"Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."